MedTrace Logo

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

NCT01355562 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-04-30

No results posted yet for this study

Summary

The current study will test single agent IL-2 in stage IV melanoma and kidney cancer.

Conditions

Interventions

DRUG

Interleukin-2 (IL-2)

Daily for 4 doses every 3 weeks for a total of 12 doses in an outpatient setting

Sponsors & Collaborators

  • Loma Linda University

    lead OTHER

Principal Investigators

  • Walter Quan, Jr., M.D. · Loma Linda University Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01355562 on ClinicalTrials.gov